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Objective: To evaluate the clinical effectiveness of intraarticular IL-1 receptor antagonist (IL-1Ra) for
anterior cruciate ligament (ACL) tear.
Methods: Eleven patients with acute ACL tear conﬁrmed by magnetic resonance imaging (MRI) were
randomized to receive a single intraarticular injection of IL-1Ra (anakinra 150 mg, n ¼ 6) or equal volume
of saline placebo (1 ml, n ¼ 5). The double-blinded treatment was administered a mean 2 weeks after
injury. Synovial ﬂuid (SF) (n ¼ 9 patients) and sera (all patients) were available at baseline (prior to
injection) and immediately prior to surgery (mean 35 days later) and analyzed for SF IL-1a, IL-1b, IL-1Ra
and serum hyaluronan (HA), an indicator of synovial inﬂammation. The primary outcome, standardized
Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, was obtained at 0 (baseline), 4, and
14 days after injection.
Results: Compared with placebo, the IL-1Ra group had substantially greater improvement in key
outcomes over 14 days (KOOS pain P ¼ 0.001; activities of daily living P ¼ 0.0015; KOOS sports function
P ¼ 0.0026; KOOS quality of life (QOL) P ¼ 0.0048; and total KOOS P < 0.0001). There were no adverse
reactions in either group. SF IL-1a (P ¼ 0.05) and serum HA (P ¼ 0.03), but not IL-1b, or IL-1Ra, decreased
signiﬁcantly in the IL-1Ra but not the placebo treated patients. Compared with placebo, IL-1a was
borderline signiﬁcantly different in the IL-1Ra treated group (P ¼ 0.06).
Conclusions: Administered within the ﬁrst month following severe knee injury, IL-1Ra reduced knee pain
and improved function over a 2-week interval. This promising proof of concept study provides a new
paradigm for studies of acute joint injury and suggests that a larger follow-up study is warranted.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Estimates suggest that approximately 12% of the overall preva-
lence of symptomatic OA is due to joint injury1,2. On average, 50% of
individuals develop radiographic osteoarthritis (OA) approximately
10e20 years after anterior cruciate ligament (ACL) or meniscal knee
injury3. However, it is increasingly recognized that biochemical
abnormalities within the joint precede radiographic abnormalities
of OA by as much as decades4e7. This not only provides the oppor-
tunity for early diagnosis of joint metabolic abnormalities prior to
their culmination in radiographic OA, but the prospect of early
intervention and treatment monitoring as well. In contrast to: V.B. Kraus, Box 3416, Duke
-919-681-6652; Fax: 1-919-
s Research Society International. Pidiopathic OA, post-traumatic arthritis is initiated by intraarticular
processes with a known date of onset, namely the date of joint
injury. Thismakes it muchmore amenable to early intervention and
early monitoring than idiopathic OA whose onset is not clearly
deﬁnable at this time.
After joint injury, it is proposed that abnormal joint motion and
loading lead to abiological responsedominatedbycatabolic activity8.
There is considerable variation in response to surgical treatment and
a lack of objective evidence to support a protective role of repair or
reconstructive surgery of the ACL or meniscus against OA develop-
ment3,9. In part, we hypothesize that this may be due to the damage
accrued by the joint during the ﬁrst month after injury, traditionally
a time for bracing and analgesics prior to surgical intervention.
Hemarthrosis often occurs in the acute phase of joint injury, is highly
toxic to the joint, and contributes to cartilage catabolism with inhi-
bition of proteoglycan synthesis after only a 4-day exposure to
mononuclear cells and erythrocytes in concentrations equivalent toublished by Elsevier Ltd. All rights reserved.
V.B. Kraus et al. / Osteoarthritis and Cartilage 20 (2012) 271e278272those in whole blood10. We hypothesized that the early biological
response of the injured joint has a crucial impact on the long-term
health consequences of the joint organ, and therefore, that the
early phase of acute injury may represent a window of opportunity
for providing treatment to promote healing and to prevent the
subsequent cascade of joint destructive processes following injury
that often culminate in arthritis.
IL-1 levels are elevated in patients with ACL rupture and
correlate with severity of chondral damage11. In this pilot study, we
therefore chose to test the effectiveness of early intervention
with an anti-cytokine therapy, interleukin-1 receptor antagonist
(IL-1Ra), to reduce knee pain and inﬂammation and improve
function. Awealth of preclinical (summarized by Calich et al. 12) and
human clinical data support the anti-arthritic therapeutic potential
of IL-1 inhibition. Preclinical data include efﬁcacy in collagen
induced arthritis in mice13e17, and therapeutic efﬁcacy of IL-1Ra in
OA models in rats18e20, dogs21,22, rabbits23, and horses24. Low
innate production of cytokines (IL-1beta, IL-1Ra and IL-6) upon
whole blood LPS stimulation are associated with low body burdens
of OA25. In addition, polymorphisms in genes encoding IL-1
receptor antagonist26,27 and IL-1 receptor28 and the IL-1 gene
cluster29e31 are associated with OA. Based on these data we chose,
in this pilot study, to investigate the effects of IL-1 inhibition on
symptoms and functioning following joint injury.
IL-1Ra is a naturally occurring IL-1 inhibitor that binds the IL-1RI
receptor without triggering an agonist response and thus functions
as a receptor antagonist. The IL-1Ra approved for human use is a
recombinant, non-glycosylated version of human IL-1Ra. It consists
of 153 amino acids and differs from native human IL-1Ra only in the
addition of a single methionine residue on its amino terminus. The
drug is sold under the tradename Kineret (Biovitrum AB, Stock-
holm) and generic name anakinra. Anakinra is Federal Drug
Administration (FDA) approved for daily subcutaneous (SC) injection
(100mg/day) for the treatmentof rheumatoid arthritis (RA). Delivery
by intraarticular injection is an attractive alternative considering it
has the potential to minimize systemic side effects of a biological
agent. Two clinical trials of IL-1Ra for established kneeOAused single
intraarticular injections and resulted in short-term beneﬁt and no
safety concerns32e34. IL-1Ra has also been shown to be beneﬁcial for
erosive hand OA35. Informed by these trials of IL-1Ra for OA, we
designed and conducted a randomized placebo-controlled pilot trial
of IL-1Ra for acute knee injury involving ACL tear.
Methods
Trial design
This was an investigator-initiated, placebo controlled, random-
ized, double-blinded proof of concept pilot trial of intraarticular
IL-1Ra (anakinra) for acute knee injury with ACL tear. The Duke
Institutional Review Board (IRB) approved this study. The investi-
gation was conducted in accordance with the principles expressed
in the Declaration of Helsinki. Upon review by the FDA, the study
was deemed exempt from the requirements of Part 312 of the
Investigational New Drug (IND) regulations as it met all of the
requisites set forth at 21 CFR 312.2(b)(1), namely that the route of
administration, dose and patient population did not signiﬁcantly
increase the risks or decrease the acceptability of the risks,
informed consent was to be obtained, the study would be IRB
reviewed and approved prior to initiation, the study was not
intended to be used to support a new indication or change in
labeling of a drug product, and the drug would not be commercially
represented as safe or effective for the purpose for which it was
under investigation. Randomization was computer-generated and
performed by a physician unconnected with the study. Thephysician study coordinator (JB) enrolled the participants. The
Duke Research Pharmacy assigned participants to the intervention
based on the randomization schedule. The trial NCT00332254
“Study to Prevent Cartilage Damage Following Acute Knee Injury”
was registered with ClinicalTrials.gov on 5.30.2006 and was con-
ducted between July 2006 and April 2007. The trial is summarized
in the CONSORT Flow Diagram (Fig. 1).
Participants
To be considered for inclusion in this trial, the following
requirements had to be met: onset of injury less than 4 weeks prior
to evaluation; severe knee injury expected to require surgery,
Magnetic Resonance Imaging (MRI) conﬁrmed ACL tear; age 18e30
years; negative serum pregnancy testing (bHCG) at time of entry
and on follow-up evaluation for women of childbearing potential
with their agreement to use some form of contraception during the
study period; and ability to provide informed consent. In addition,
all participants had to be non-obese to minimize risk of pre-
existing OA. Exclusion criteria for this study were: prior signal
joint injury requiring medical evaluation; history of arthritis or
rheumatic disease; history of intraarticular corticosteroid in the
index joint; septic joint; evidence of chronic joint disease by plain
radiograph; or fracture. Study participants were identiﬁed through
the Duke University Sports Medicine clinic and by screening MRIs
for acute knee injury.
Intervention
A total of 11 patients were treated within the ﬁrst 30 days of
acute knee injury: six patients were randomized to intraarticular
IL-1Ra (anakinra 150 mg) and ﬁve patients to intraarticular saline
placebo (1ml). This dosewas chosen on the basis of an in vivo phase
I, intraarticular dose-escalating study by Chevalier et al.32 wherein
the maximum possible intraarticular dose used, 150 mg, was
administered without adverse events; this dose was based on
previous maximum dose administered subcutaneously for RA32,36.
The Duke Research Pharmacy supplied the drug or placebo in
solutions of equal volume (1 ml volume), color and consistency in
syringes ready for injection, making the interventions indistin-
guishable to patients and study personnel in charge of adminis-
tering the agents. In addition, prior to surgery, all subjects were
prescribed standard conservative therapy that included knee
bracing (n ¼ 6), non-steroidal anti-inﬂammatory drugs (NSAIDs)
(as needed Ibuprofen n ¼ 5), analgesics (acetaminophen n ¼ 2,
hydrocodone n ¼ 1), ice (n ¼ 3), and range of motion exercise and
quadriceps strengthening (n¼ 6). These interventions did not differ
by treatment group (Table I).
Clinical outcomes
The designated primary outcome was change over time in
standardized Knee Injury and Osteoarthritis Outcome Score (KOOS)
scores obtained at baseline (0), 4, 14, and 28 days after study
enrollment. The KOOS scores were normalized as speciﬁed in the
KOOS investigators instructions found at www.koos.nu/
KOOSGuide2003.pdf. The higher KOOS scores represent less pain
and better function. The majority of participants (8/11) underwent
surgical repair prior to the 28 day post-enrollment timepoint so 28-
day KOOS data were not available for analysis.
Sample collection
Blood for serum was collected at baseline (n ¼ 11) and at the
time of ACL reconstructive surgery (n ¼ 11) and stored at 80C
Fig. 1. Consort Flow Diagram. This shows the ﬂow of participants through each stage of the randomized pilot trial of intraarticular IL-1Ra (anakinra) vs saline for acute ACL
tear injury.
Table I
Clinical characteristics by intervention group
Characteristic IL-1Ra (n ¼ 6) Placebo (n ¼ 5)
Mean (SD) age years 22 (3) 24 (4)
Female 2 3
Intra-articular pathology
by clinical MRI
Two isolated ACL tears; two ACL tears with
partial medial collateral ligament tears;
two ACL tears with meniscal tears
One isolated ACL tear; one ACL tear with partial
medial collateral ligament tear; two ACL tears with
meniscal tears; and one ACL tear with medial
collateral ligament and meniscal tears
Standard care Knee bracing (n ¼ 3), NSAIDs (as needed
Ibuprofen n ¼ 2), ice (n ¼ 2), and range of
motion exercise and quadriceps
strengthening (n ¼ 2).
Knee bracing (n ¼ 3), NSAIDs (as needed
Ibuprofen n ¼ 3), analgesics (acetaminophen
n ¼ 2, hydrocodone n ¼ 1), ice (n ¼ 1), and range
of motion exercise and quadriceps strengthening (n ¼ 4).
Mean/median (SD) days from
injury to enrollment
13/14 (6) 17/17 (9)
Mean/median (SD) days between baseline
and follow-up sample collection
20/22 (9) 53/40 (40)
Mean/median (SD) days between
injury and surgery
33/34 (12) 70/67 (46)
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baseline from the injured knee (n ¼ 11), the syringe was changed
and the drug or placebo was injected. Neat SF was also aspirated
from the injured knee at the time of surgical reconstruction (n¼ 9).
SF was centrifuged at 3500 rpm for 15 min and the supernatants
stored at 80C until analysis.
Biomarker assays
Secondary exploratory outcomes included analysis of SF
concentrations of IL-1a, IL-1b, IL-1Ra and serum hyaluronan (HA) in
baseline samples and samples obtained on the day of surgery. A total
of nine pairs of SFs and eleven pairs of sera were available for
biomarker analyses. IL-1a, IL-1b, and IL-1Ra were quantiﬁed by
sensitive commercially available sandwich ELISAs (R&DQuantikine).
Manufacturer reported intra- and inter-assay CVs were: 2% and 4%
for serum IL-1a; 4% and 7% for IL-1b; and 5% and 9% for IL-1Ra. The
minimal detectable concentration per the manufacturer’s instruc-
tions was 3.9 pg/ml for IL-1a, however we were able to markedly
improve the sensitivity of the IL-1a immunoassay by using an
extended initial incubation time (overnight at 4C with shaking)
coupled with an expanded standard curve in the low range, which
we found to be linear. With these modiﬁcations, the minimum
detectable concentrations were 0.05 pg/ml (IL-1a); 1.6 pg/ml (IL-
1b); and 6.26 pg/ml (IL-1Ra). Serum levels of HA were quantiﬁed
using a commercially available assay (Corgenix). Intra- and inter-
assay CVs were 2% and 3%, respectively. Biomarker measurements
were performed blinded to treatment group assignment.
Statistical analysis
The trial was unblinded after 11 patients were treated to deter-
mine whether the results merited seeking external funding and
proceeding with a larger trial. Analysis of Covariance (ANCOVA) was
used to compare the regression models of clinical KOOS outcomes
over time (over ﬁrst 14 days) in different treatment groups (drug vs
placebo). The 95% conﬁdence intervals (CIs) for the slope of response
over time for each treatment and KOOS (total and subdomain) were
computed. The non-parametric Wilcoxon SignedeRank sum test
was used to evaluate the change in biomarkers over time within
a group and to compare the change in biomarker concentrationsAnakinra Timecourse
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Fig. 2. Clinical KOOS outcomes. The panels show mean (error bars are standard deviations) o
of the IL-1 receptor antagonist anakinra (left panel) and saline placebo (right panel). The a
anakinra compared with the placebo treated group.between groups (drug vs placebo). All analyseswere by pre-assigned
group. A P value0.05was considered signiﬁcant. Based on theﬁxed
sample size of 11, a post hoc power calculation with the type I error
rate set at 5% shows the study had 80% power to detect an effect size
of 0.4 in KOOS outcomes.
Results
Participant characteristics
Patients were recruited a mean 15  7 (SD) days from injury
(range 6e27 days post-injury). The mean age of participants (six
male, ﬁve female; two African American) was 24 4 (SD) years. The
clinical characteristics of each group are summarized in Table I. For
this pilot study, enrollment was limited to patients under 30 years
of age to try to ensure the lack of an underlying pre-existing
arthropathy. Participants suffered acute knee injuries secondary
to skiing (3), soccer (2), basketball (1), ultimate Frisbee (1), rugby
(1), ﬂag football (1), running (1), and a fall while cheerleading (1).
Clinical knee MRIs were performed revealing ACL tears in all
patients with the following additional intra-articular pathologies:
three patients with isolated ACL tear only; three patients with
medial collateral ligament and ACL tears; four patients with
meniscal and ACL tears; and one patient with medial collateral
ligament, meniscal and ACL tears. These combination pathologies
were equally distributed by group and the types of lesions in each
group are summarized in Table I.
Primary clinical outcomes
Improvements over time in all ﬁve subscales of the KOOS were
evident in the IL-1Ra treated but not the placebo treated patients
(Fig. 2). The IL-1Ra group had substantially greater improvement
(w1e3 standard deviations) in key outcomes whereas the placebo
group had much less improvement (w1/4 of a standard deviation
on most outcomes). Relative to the placebo treated group, there
was a statistically signiﬁcant improvement in the anakinra treated
group in KOOS pain, KOOS function in daily living (ADL), KOOS
Sports Function, KOOS knee related quality of life (QOL) and total
KOOS (Table II). In the IL-1Ra treated group, the extent of
improvements (increases in KOOS subscale scores relative toPlacebo Timecouse
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Fig. 3. Biomarker analyses. Biomarker results at baseline and time of surgery in the
intraarticular IL-1Ra treatment group (left panel) and the intraarticular saline placebo
treatment group (right panel). A) SF IL1a, B) SF IL1b, C) SF IL1-Ra, D) serum HA. Non-
parametric Wilcoxon SignedeRank sum tests were used to evaluate change scores
within a group (P values shown in ﬁgure), and change scores between groups (drug vs
placebo): IL-1a P ¼ 0.06, IL1b P ¼ 0.61, IL1-Ra P ¼ 0.27 and HA P ¼ 0.29.
Table II
KOOS clinical outcomes
KOOS Subscaley Between
Group
p value*
Mean (SD)
baseline
Mean (SD)
4 days
Mean (SD)
14 days
95% CIs for slope of the
response over time
Mean (SD)
baseline
Mean (SD)
4 days
Mean (SD)
14 days
95% CIs for slope of
the response over time
Anakinra treatment (n ¼ 6) Placebo treatment (n ¼ 5)
Pain P[ 0.0011 53.7 (20.2) 64.3 (12.1) 73.6 (16.6) (5.5141, 15.0626) 63.3 (7.2) 65.0 (5.8) 64.4 (11.1) (4.0008, 5.1128)
Other Symptoms P ¼ 0.4540 51.8 (21.0) 57.1 (25.3) 70.5 (20.3) (2.1869, 13.5031) 45.0 (19.3) 55.0 (18.8) 55.0 (14.6) (0.3847, 10.3847)
ADL P[ 0.0015 66.2 (21.2) 81.6 (10.4) 89.0 (9.2) (6.1131, 17.5111) 67.9 (10.7) 70.0 (4.5) 68.5 (10.6) (5.1625, 5.7525)
Sports Function P[ 0.0026 5 (6.3) 21.7 (24.6) 36.3 (34.7) (7.3955, 22.8768) 13.0 (18.6) 12.0 (12.0) 13.0 (16.0) (7.3985, 7.3985)
QOL P[ 0.0048 19.8 (26.9) 27.1 (24.3) 35.9 (30.4) (3.5742, 12.4005) 16.3 (11.4) 21.3 (13.7) 17.5 (12.0) (3.5691, 4.8191)
Total P < 0.0001 49.4 (18.6) 61.5 (15.4) 71.3 (16.8) (7.1387, 14.5874) 51.7 (9.8) 54.8 (3.7) 53.9 (8.6) (2.4133, 4.6753)
KOOS Subscales: Pain; Other Symptoms (such as knee swelling, clicking catching and stiffness); ADL ¼ Function in Daily Living.
Sports Function ¼ Function in Sport and Recreation; QOL ¼ knee related Quality of Life; and Total ¼ combination of all ﬁve subscales.
* P value by Repeated Measures ANCOVA (analysis was by assigned group). Values in bold are signiﬁcant at the p<0.05 level.
y Normalized KOOS scores (%).
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Function 626%, QOL 81%, and total KOOS of 44%; in contrast the
placebo group changed only 2%, 1%, 0%, 1% and 4% in these
outcomes respectively. There were no adverse events associated
with the injections or drug treatment and no discernible difﬁculties
or delays in wound healing following surgical repair.
Secondary biomarker outcomes
To explore the possible biological impact of a single IL-1Ra
intraarticular injection, we measured SF IL-1a, IL-1b, and IL-1Ra,
and serum HA, an indicator of synovitis, in samples obtained
prior to study drug injection and on the day of surgery. Pre- and
post-treatment SF samples were available from ﬁve IL-1Ra treated
patients and four placebo treated patients. The mean (SD) SF
volumes (ml) obtained were similar in both treatment groups:
baseline 14.9  4.3 and 13.0  9.9 for anakinra and placebo
respectively; follow-up 21.1  16.4 and 16.0  9.9 for anakinra and
placebo respectively. SF analyte concentrations exceeded serum
concentrations (mean  SD pg/ml): IL-1a SF 0.24  0.25 vs serum
0.05 0.11; SF IL-1b 0.77 0.51 vs serum 0.20 0.10; and SF IL-1Ra
5429  11305 vs serum 408  156. The change with treatment
(Time 1 to Time 2) in SF IL-1a constituted the most intriguing
and promising cytokine result from this pilot trial (Fig. 3). IL-1a
increased over time in all the placebo treated patients (n ¼ 4 pairs
of samples available), whereas IL-1a decreased in 4 of 5 of the
IL-1Ra treated patients (n¼ 5 pairs of samples available). Relative to
the placebo treated group, the change in SF IL-1a from baseline to
follow-up in the anakinra group was of borderline signiﬁcance
(P ¼ 0.06). The change in IL-1b and IL-1Ra were not signiﬁcant in
either treatment group. Pre- and post-treatment serum samples
were available from all six IL-1Ra treated patients and the ﬁve
placebo treated patients. Serum HA decreased from baseline to
follow-up in all the IL-1Ra treated patients (Fig. 3, P ¼ 0.03) but did
not change signiﬁcantly in the placebo treated group and was not
signiﬁcantly different between treatment groups.
Discussion
As shown by this small, randomized pilot trial, intraarticular
IL-1Ra decreased pain and improved function (ADL, Sports Function
and QOL) following acute knee injury. A minimal perceptible clin-
ical improvement of 9e12 mm (based on a 100 mm Visual
Analogue Scale (VAS)) on Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) scales of pain, physical func-
tion and stiffness has been established as a perceptible change to
patients with hip and knee OA37. Since the KOOS dimension of ADL
is equivalent to that of Function in theWOMACOsteoarthritis Index
LK 3.038, the WOMAC metric for clinically important difference canbe applied directly to the normalized ADL scores achieved with
KOOS. We observed a mean (SD) change (improvement) of 22.2
(11.8) points in KOOS ADL scores over 14 days in the IL-1Ra treated
group compared with mean (SD) change of only 0.6 (14.4) points in
the placebo treated group. Thus this trial exceeded the minimal
perceptible clinical improvement in ADL that has been established
for the WOMAC. A change in normalized KOOS scores of 8e10
V.B. Kraus et al. / Osteoarthritis and Cartilage 20 (2012) 271e278276points has also been suggested to represent a minimal perceptible
clinical improvement following ACL reconstruction38. In this pilot
study we observed this level of change in normalized KOOS scores
in all the KOOS subscales in the IL-1Ra treated group (range mean
15.2e30 point change from baseline to 14 days) but only in
symptoms (mean 10 point change) in the placebo treated group
(remaining subscales yielded only mean changes ranging from 0.6
to 2.3 points in the placebo treated group). Thus, based on either
metric, the magnitude of change in KOOS subdomains achieved by
IL-1Ra would indicate a clinically meaningful improvement in this
small pilot study.
In the prior Phase I, dose-escalating study of IL-1Ra (anakinra)
for knee OA32, a signiﬁcant response (responder deﬁned as having
a 50% reduction from baseline) was observed at 1 month following
a single intraarticular injection in the VAS pain outcome in 7 of 13
patients, and in the global WOMAC outcome in 10 of 13 patients. By
3 months post injection, there were six responders for each
outcome. There were no acute reactions and no injection site
reactions. One patient had a sterile effusion (150 cells/mm3) within
3 days post injection without pain that resolved spontaneously;
this episodewas deemed by the study investigator tomost likely be
unrelated to the drug. Following the pilot study they performed
a randomized controlled trial (n ¼ 170)39 in which no safety
concerns were raised. It did not replicate the clinical beneﬁt re-
ported in the initial pilot study based on the main outcome of pain
at 1 month; however, there was apparent improvement in the
150 mg group at Day 434. They interpreted these results to be in
keeping with the short half-life of IL-1Ra suggesting that IL-1
inhibition may be therapeutically relevant, and postulated that
longer term therapy might be required for a more sustained effect.
Peak plasma concentrations of anakinra are reached 3e7 hours
after subcutaneous (SC) injection with a half-life of 4e6 h40. After
IL-1Ra is discontinued, simulations indicate that it takes approxi-
mately 3 days for the IL-1Ra concentration to decline to a level
below the lower limit of quantiﬁcation. Compared with the saline
treated group, the anakinra group showed steady improvement in
KOOS outcomes during the 14 days following a single intraarticular
injection suggesting that early intervention, even with a short-
acting agent, may result in clinical beneﬁt in the setting of acute
knee injury Table II.
Taken together with the wealth of preclinical and clinical data,
this study increases conﬁdence in IL-1 as a promising target for
symptom and potential disease modiﬁcation following severe joint
injury. We speculate that repeated injections of a short-acting IL-1
inhibitor or a longer-acting agent may be required to optimally
block cartilage degradation and ultimately lessen the risk of
arthritis development.With respect to anakinra, themain barrier to
overcome is drug retention in the joint. Means of overcoming this
problem (summarized by MartelePelletier et al.41) include: the use
of repeated intraarticular injections of anakinra such as on aweekly
basis; combining anakinra with a sustained release system19, and
exploration of the effectiveness of SC injections of the drug (the FDA
approved method of delivery for the treatment of RA)41. The chal-
lenge will be to deliver an agent with a long enough half-life to
minimize the number of joint injections andmaximize the prospect
of blocking joint degradation during the critical immediate post-
joint injury period and possibly immediate post-surgical repair
period of inﬂammation without increasing the risk of infections in
the setting of surgery.
The delay in surgical reconstruction of the ACL is typically
predicated on the attempt to prevent arthroﬁbrosis. This approach
is supported by evidence that performing surgerywithin 4weeks of
ACL injury is a risk factor for post-operative development of
arthroﬁbrosis42e44. Mayr et al. found that the presence of knee
irritation pre-operatively (swelling, effusion, hyperthermia)correlated (P ¼ 0.001) with development of arthroﬁbrosis45.
Furthermore, they found that if joint irritation persisted after 4
weeks, the risk of arthroﬁbrosis remained elevated. They concluded
that it is inﬂammation, andnot timing of the surgery,which predicts
development of arthroﬁbrosis post-operatively. Therefore, attempts
to reduce preoperative inﬂammation were recommended as the
critical intervention in preventing this difﬁcult post-surgical
complication. At present, there are no speciﬁc therapies for the
reduction of pre- and peri-operative joint inﬂammation in humans
beyond general measures such as NSAIDs, icing, and bracing46.
However, in antigen-induced arthritis in rabbits, IL-1Ra had
a profound antiﬁbrotic effect47. In this model, the synovial ﬁbrosis
was not only halted by administration of IL-1Ra but it was
reversed47.
SF IL-1a decreased over 1 month in response to a single IL-1Ra
intraarticular injection in our pilot trial. The decrease in SF IL-1a
in the IL-1Ra treated patients likely represents downregulation of
IL-1a expression by synovium in response to IL-1Ra therapy. This
mechanism of action of IL-1Ra is supported by in vitro work by
Haupt and Evans et al.48. IL-1 is particularly important at the local
level and more potent than tumor necrosis factor alpha in stimu-
lating matrix metalloproteinases and speciﬁcally impeding carti-
lage repair49. It is known50 that IL-1a binds the membrane bound
form of IL-1RI in preference to the soluble form. Moreover, IL-1Ra
binds IL-1RI nearly irreversibly. In contrast, the binding of IL-1b
to the decoy receptor, IL-1RII, is nearly irreversible. The known
differential binding afﬁnities of these receptors for the IL-1 family
of cytokines have great relevance for this study because they make
it clear that IL-1Ra has a preference for IL-1RI receptor and there-
fore would preferentially block IL-1 from signaling through the
functional receptor. These data also suggest that IL-1a, despite low
absolute concentrations in the SF in acute joint injury may have
great functional relevance by virtue of its binding afﬁnity for the
membrane bound functional receptor. The promising results with
SF IL-1a suggest that IL-1 inhibition in the immediate post-injury
period may reduce joint destructive inﬂammation. Therefore,
optimization of this approach may, in future, allow for earlier
surgical intervention without increasing the risk for arthroﬁbrosis.
This study has several limitations including the small study size,
and the short half-life of the compound used. Since this study was
conducted, two longer acting anti-IL-1 agents, Rilonacept and
Canakinumab (a fully humanized anti-IL-1beta monoclonal anti-
body51), received FDA Orphan Drug approval for treatment of rare
human autoimmune cryopyrinopathies, with 7-day and one-
month half-lives respectively; these might provide a viable longer
acting alternative to IL-1Ra. Other anti-IL-1 strategies that might
also be considered include sustained intraarticular delivery of
IL1-Ra19 (not yet approved for human use), Orthokine52e54, and
intraarticular gene therapy delivery of IL-1Ra (used without
adverse events in RA)55,56. This study was also limited by the
difference in follow-up times between groups that would have
impacted the SF biomarkers but not the clinical outcome data; this
would be expected to have resulted in a naturally lower level of
inﬂammatory markers in the placebo group and biased against
ﬁnding a difference in biomarkers due to drug treatment. Despite
these limitations, this study was designed as a proof of concept trial
and in that regard it has succeeded in providing a paradigm by
which the utility of biological agents for acute joint injury may be
tested. Together these two approaches, biological therapies to
minimize joint destruction and inﬂammation and allowing for the
possibility of earlier surgical repair, constitute a new treatment
paradigm that deserves to be stringently tested to determine
whether this approach could decrease the incidence of post-
traumatic arthritis. Analogous to the treatment paradigm for
acutemyocardial infarction, in future, an acute joint injurymight be
V.B. Kraus et al. / Osteoarthritis and Cartilage 20 (2012) 271e278 277treated emergently to prevent joint damage in order to preserve
long-term full joint organ function.
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